Molecular Insight Pharma Inc. (MIPI) reported one-year follow-up data from a Phase I dose-escalation clinical study of Azedra. The company said the study demonstrated a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers, pheochromocytoma and paraganglioma.
The study was designed to evaluate the safety and identify the maximum tolerated dose of Azedra, as well as to collect clinical data on efficacy. In the 12-month data reported, a single dose of Azedra was shown to be well tolerated by patients, and toxicities were predictable and manageable. Azedra demonstrated clinical benefit, stabilizing or reducing tumor volumes in a majority of patients.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.